Compare DuPont de Nemours Inc (DD) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Illumina, Inc. — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.89B), while Illumina, Inc. trades at $266.99 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.2× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Illumina, Inc. for 83 Days on average.
| DD | ILMN | |
|---|---|---|
Market Cap | $17.89B | $39.95B |
Volume | 816,409 | 3,169,503 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $293.69 |
52-Week Low | $92.49 | $91.00 |
Typical Hold Time | 89 Days | 83 Days |
Enterprise Value | $19.28B | $41.31B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.
The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
